L Ryvo

738 total citations · 1 hit paper
8 papers, 544 citations indexed

About

L Ryvo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, L Ryvo has authored 8 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in L Ryvo's work include Advanced Breast Cancer Therapies (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cancer Treatment and Pharmacology (3 papers). L Ryvo is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cancer Treatment and Pharmacology (3 papers). L Ryvo collaborates with scholars based in Israel, Japan and United States. L Ryvo's co-authors include Rita Nanda, Kenji Tamura, Hirofumi Mukai, Peter Schmid, Vassiliki Karantza, Hiroji Iwata, Sherene Loi, Antoinette R. Tan, Pauline Wimberger and Michelino De Laurentiis and has published in prestigious journals such as Cancer Research, Annals of Oncology and Journal of Geriatric Oncology.

In The Last Decade

L Ryvo

8 papers receiving 537 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L Ryvo Israel	5	462	173	167	140	95	8	544
Hanne Lind United States	5	336 0.7×	128 0.7×	152 0.9×	134 1.0×	150 1.6×	7	496
M. Nechaeva Russia	8	326 0.7×	164 0.9×	104 0.6×	100 0.7×	57 0.6×	17	401
M.C. Liu United States	3	418 0.9×	158 0.9×	159 1.0×	126 0.9×	79 0.8×	7	490
Lisa Flaum United States	11	370 0.8×	207 1.2×	81 0.5×	299 2.1×	127 1.3×	32	535
Sara Jansson Sweden	8	374 0.8×	92 0.5×	123 0.7×	209 1.5×	132 1.4×	13	491
Katrin Almstedt Germany	12	270 0.6×	95 0.5×	95 0.6×	119 0.8×	125 1.3×	33	403
Xianping Yi China	4	476 1.0×	342 2.0×	143 0.9×	160 1.1×	195 2.1×	9	680
A. Swat Switzerland	4	305 0.7×	135 0.8×	89 0.5×	112 0.8×	45 0.5×	6	354
Jean‐Nicolas Lodewyckx Belgium	4	351 0.8×	63 0.4×	277 1.7×	56 0.4×	86 0.9×	7	455
Pauline Maby France	6	328 0.7×	67 0.4×	184 1.1×	94 0.7×	116 1.2×	7	459

Countries citing papers authored by L Ryvo

Since Specialization

Citations

This map shows the geographic impact of L Ryvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Ryvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Ryvo more than expected).

Fields of papers citing papers by L Ryvo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Ryvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Ryvo. The network helps show where L Ryvo may publish in the future.

Co-authorship network of co-authors of L Ryvo

This figure shows the co-authorship network connecting the top 25 collaborators of L Ryvo. A scholar is included among the top collaborators of L Ryvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Ryvo. L Ryvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2018). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology. 30(3). 405–411. 460 indexed citations breakdown →

2.

Adams, Sylvia, Sherene Loi, D. Toppmeyer, et al.. (2018). Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC). Cancer Research. 78(4_Supplement). PD6–10. 22 indexed citations

3.

André, Fabrice, Bella Kaufman, Dejan Juric, et al.. (2017). Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy. Cancer Research. 77(4_Supplement). OT2–1. 1 indexed citations

4.

André, Fabrice, Bella Kaufman, Dejan Juric, et al.. (2016). A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1). Annals of Oncology. 27. vi98–vi98. 2 indexed citations

5.

Stemmer, Salomon M., Shulamith Rizel, Lior Soussan‐Gutman, et al.. (2016). Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%. Cancer Research. 76(4_Supplement). P5–8. 15 indexed citations

6.

Hasson, Shira Peleg, Tamar Rubinek, L Ryvo, & Ido Wolf. (2013). Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway. Breast Care. 8(4). 248–255. 39 indexed citations

7.

Ryvo, L, Beatrice Uziely, David Geffen, et al.. (2013). Recurrence score results in elderly patients with estrogen receptor positive early breast cancer. Journal of Geriatric Oncology. 4. S33–S33. 1 indexed citations

8.

Safra, Tamar, Bella Kaufman, Joel Greenberg, et al.. (2012). Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study. Cancer Research. 72(24_Supplement). P5–20. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact